Preoperative and Postoperative Sublingual Misoprostol for Prevention of Postpartum Blood Loss in Cesarean Section

Comparison Between Preoperative and Postoperative Sublingual Misoprostol for Prevention of Postpartum Blood Loss in Cesarean Section : a Randomized Clinical Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03591913

Enrollment

500

Registered

2018-07-19

Start date

2018-02-01

Completion date

2018-09-01

Last updated

2018-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Hemorrhage

Brief summary

Cesarean section is one of the most common major surgical operations among women. In 2015, the incidence of cesarean section in Woman Health Hospital in Assiut University accounts for 51.3 % of all deliveries

Interventions

DRUGMisoprostol

Oral tablets

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* All pregnant women who will undergo elective lower segment cesarean section * term ( ≥ 37 weeks) * normal fetal heart tracing.

Exclusion criteria

* Placenta previa-Rupture uterus * Classical cesarean section * Preterm delivery * Hypertensive disorders of pregnancy * Bleeding tendency * Previous history of postpartum hemorrhage * Concurrent anticoagulant therapy * Concurrent long-term use of steroids * Fetal distress * Antepartum haemorrhage

Design outcomes

Primary

Measure	Time frame	Description
mean intraoperative blood loss	24 hours	Blood loss estimation will commence immediately following the skin incision

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026